SCHEMBL14728992

SCHEMBL14728992

CC(C)(O)CCS(=O)(=O)N1CC=C(c2ccc3nc(OC4CCN(Cc5ccccc5)CC4)sc3c2)CC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.47
BCHE P06276 2/20 0.39
ACHE P22303 2/20 0.39
LTA4H P09960 6/20 0.37
CHEK2 O96017 1/20 0.37
SCN1A P35498 2/20 0.36
SCN8A Q9UQD0 2/20 0.36
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36
DRD3 P35462 1/20 0.36
MMP2 P08253 4/20 0.36
MMP3 P08254 4/20 0.36
KCNH2 Q12809 4/20 0.36
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MGLL Q99685 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2585277 0.90 GPR119 (0.57) GPR119BCHEACHELTA4HCHEK2
SCHEMBL14728978 0.86 SCD (0.39) GPR119ALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL14729163 0.86 GPR119 (0.40) GPR119MMP2MMP3
SCHEMBL14728966 0.86 GPR119 (0.41) GPR119MMP2MMP3
SCHEMBL14728983 0.86 GPR119 (0.41) GPR119MMP2MMP3
SCHEMBL14729170 0.85 GPR119 (0.38) GPR119MMP2MMP3
SCHEMBL14729012 0.85 GPR119 (0.38) GPR119MMP2MMP3
SCHEMBL14728998 0.85 GPR119 (0.50) GPR119
SCHEMBL14728917 0.84 GPR119 (0.49) GPR119
SCHEMBL14728964 0.84 GPR119 (0.40) GPR119MMP2MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8940716-B2 Bicyclic heteroaryl compounds as GPR119 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2015-01-27 US disclosed
US-8940716-B2 Bicyclic heteroaryl compounds as GPR119 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2015-01-27 US disclosed
US-20130053345-A1 BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2013-02-28 US disclosed
US-20130053345-A1 BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053345-A1 BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS GPR119, GPR139, GPR4 GPR119 1/4885BCHE 3255/4885ACHE 4189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.